Kymera Therapeutics Stock Surges on Early Trial Enrollment Completion
Kymera Therapeutics (NASDAQ: KYMR) saw its stock rise nearly 30% over five trading days after announcing the early completion of enrollment in a key Phase 2b trial for KT-621, an experimental drug for severe atopic dermatitis. The topline data is now expected by year-end instead of mid-2027, prompting analyst price target raises.
Tickers: $KYMR
Topics: atopic_dermatitis biotech targeted_protein_degradation